BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GUB-UCN2 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GUB-UCN2\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07702890-170@assetmemo.bio
DTSTAMP:20261121T005451Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:GUB-UCN2: Phase 1/2 readout est. (NCT07702890)
DESCRIPTION:GUB-UCN2\, phase 1/2\, Obesity.\nStudy: A Three-part First-in-h
 uman Trial to Assess Safety\, Tolerability\, Pharmacokinetics and Pharmaco
 dynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participan
 ts With T2D\nEstimated primary completion: December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/gub-ucn2#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07702890
URL:https://assetmemo.bio/drug/gub-ucn2#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
